Multiple Myeloma and Pomalidomide
- Pomalidomide is a medication used in the treatment of multiple myeloma,
- a type of cancer that affects plasma cells, a type of white blood cell found in the bone marrow.
- Multiple myeloma is characterized by the uncontrolled growth of abnormal plasma cells,
- which can lead to bone damage, anemia, kidney problems, and weakened immune function.
- Pomalidomide is classified as an immunomodulatory drug
- and belongs to a class of medications known as thalidomide analogs.
- It works by inhibiting the growth and survival of myeloma cells and modulating the immune system to help fight against the cancer.
- extend progression-free survival in patients with relapsed or refractory multiple myeloma.
- It has demonstrated the ability to control disease progression and increase the duration of remission in some cases.
- As with any medication, pomalidomide may cause side effects.
- Common side effects include fatigue, nausea, diarrhea, constipation, decreased appetite, low blood cell counts, infections, and blood clotting disorders.
- Regular blood tests and close monitoring of patients receiving pomalidomide are necessary to ensure optimal treatment outcomes and manage any potential side effects.
- Healthcare providers typically develop personalized treatment plans based on the individual needs of each patient.